Biotricity, Inc. (BTCY) Q2 2026 Earnings Call Transcript

Revenue $3.9 million for Q2 FY2026, a 19% increase year-over-year from $3.3 million. This growth is attributed to strategic initiatives and technological advancements.

Gross Profit $3.2 million for Q2 FY2026, a 29.4% increase year-over-year from $2.5 million. Gross profit percentage improved to 81.9% from 75.3%, driven by recurring technology fee revenue, AI efficiencies, and cost structure improvements.

Operating Expenses $2.9 million for Q2 FY2026, a 5.1% increase year-over-year from $2.8 million. SG&A expenses rose by 2.5% ($56,000), and R&D expenses increased by $84,000.

EBITDA $373,000 for Q2 FY2026, marking the second consecutive quarter of positive EBITDA. This improvement reflects revenue growth, operating efficiencies, and cost management.

Net Loss $772,000 for Q2 FY2026, a reduction from $1.6 million year-over-year. Loss per share decreased to $0.29 from $0.73, driven by improved operating results and cost-cutting measures.